Picture of Cellectar Biosciences logo

CLRB Cellectar Biosciences Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m+29.61%
3m+53.37%
6m+20.05%
1yr-24.87%
Volume Change (%)
10d/3m+113.09%
Price vs... (%)
52w High-42.66%
50d MA+39.54%
200d MA+8.8%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-124.81%
Return on Equity-78.88%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Cellectar Biosciences EPS forecast chart

Profile Summary

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through Phospholipid Drug Conjugate (PDC) platform, is focused on to develop PDCs that are designed to target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The Company’s product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The Company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase II CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase II CLOVER-2 study.

Directors

Last Annual
December 31st, 2021
Last Interim
June 30th, 2022
Incorporated
June 24th, 1996
Public Since
January 28th, 2008
No. of Shareholders
245
No. of Employees
12
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
6,110,123
Blurred out image of a map
Address
100 Campus Drive, FLORHAM PARK, 07932
Web
http://cellectar.com
Phone
+1 6084418120
Auditors
Baker Tilly Virchow Krause, LLP

CLRB Share Price Performance

Upcoming Events for CLRB

Q3 2022 Cellectar Biosciences Inc Earnings Release

Similar to CLRB

Picture of Aadi Bioscience logo

Aadi Bioscience

us flag iconNASDAQ Capital Market

Picture of Acasti Pharma logo

Acasti Pharma

us flag iconNASDAQ Capital Market

Picture of Adamis Pharmaceuticals logo

Adamis Pharmaceuticals

us flag iconNASDAQ Capital Market

Picture of Affinia Therapeutics logo

Affinia Therapeutics

us flag iconNASDAQ Capital Market

Picture of Agriforce Growing Systems logo

Agriforce Growing Systems

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email